The following is in the Annual Report.The fact that they paused...

The following is in the Annual Report.
The fact that they paused trading means they didn't know. It maybe difficult to get any cash out of Roquefort.
They could owe us 4%+8% =12% on upfront payment of $10MUS or $15M AUD or $1.8M AUD.

Then a % on any revenue.

Need to see the fine print of any agreement, it may on be 4% upfront.

I do smell trouble though.
The Company’s intellectual property portfolio continues to include its ownership of midkine patents and one midkine patent
application. These assets are the subject to a license agreement which continues between Anagenics and Lyramid (a former
owned business subsequently acquired by Roquefort Therapeutics Plc in December 2021). The license arrangement provides
Anagenics a royalty payment of 4.0% payable on every sale of products developed and sold with an additional 8.0% payable on
any revenue sub licensed to another party. Once successfully commercialised the benefits under the license agreement should
provide Anagenics with an ongoing royalty income stream based on sales made.
Other granted patents
The Company’s intellectual property portfolio continues to include its ownership of midkine patents and one midkine patent
application. These assets are the subject to a license agreement which continues between Anagenics and Lyramid (a former
owned business subsequently acquired by Roquefort Therapeutics Plc in December 2021). The license arrangement provides
Anagenics a royalty payment of 4.0% payable on every sale of products developed and sold with an additional 8.0% payable on
any revenue sub licensed to another party. Once successfully commercialised the benefits under the license agreement should
provide Anagenics with an ongoing royalty income stream based on sales made.
Other granted patents relating to the Group’s consumer health business include midkine for hair loss and FGF5 and
monoterpenoid claims. Along with these assets and ownership of key brands, Anagenics continues to have a strong and
differentiating position in the market enabling it to share in these benefits as they realise in the future.